ライフサイエンスコーパス: immunisation

1 achieving full protection with a single dose immunisation.

2 verse events were associated with receipt of immunisation.

3 and immunogenicity at day 42 after the first immunisation.

4 gestational age infants was not modified by immunisation.

5 equiring hospitalisation were reported after immunisation.

6 cine-NP and IAV groups following the booster immunisation.

7 o prioritise research directions in maternal immunisation.

8 blingually delivered antigen than intranasal immunisation.

9 ered by intramuscular injection or Nanopatch immunisation.

10 and heterologous boosting of parenteral BCG immunisation.

11 or gaps in optimum diagnosis, treatment, and immunisation.

12 children are unlikely to benefit from active immunisation.

13 to each of the four vaccine components after immunisation.

14 ssment criteria for adverse events following immunisation.

15 nal correlates of attachment patterns during immunisation.

16 te molecular mechanisms deemed necessary for immunisation.

17 individuals, and the group-level benefits of immunisation.

18 eous cancers, and for intracutaneous genetic immunisation.

19 boosted in vaccinees that received a second immunisation.

20 Opa were specific to the Opa variant used in immunisation.

21 r before to bring about these innovations in immunisation.

22 infant response to BCG, tetanus, or measles immunisation.

23 ho were born at least 28 days after maternal immunisation.

24 in children regardless of serostatus before immunisation.

25 omologous (Group 3, intradermal-intradermal) immunisation.

26 low level to non-lymphoid tissues after skin immunisation.

27 ds of mortality (2.02 [1.23-3.32]) and lower immunisation (0.34 [0.24-0.47]) than did Han children.

28 After immunisation, 11 (92%) of 12 vaccine-treated participant

29 We studied 14 outcomes-children's immunisations, accidents, language development, positive

30 pants were excluded from local supplementary immunisation activities during the study period.

31 V shows a potential role for this vaccine in immunisation activities to accelerate eradication and pr

32 Coverage estimates for immunisation activities were also obtained, allowing for

33 d through polio surveillance, information on immunisation activities with different oral poliovirus v

34 Supplementary immunisation activities with oral poliovirus vaccines (O

35 munity, based on these estimates and planned immunisation activities, were produced through to April

36 3 years after a measles supplemental immunisation activity (SIA), we undertook a cross-sectio

37 dline, and after each round of supplementary immunisation activity for acceptability and effect.

38 uch as WHO but also a well informed national immunisation advisory committee with access to appropria

39 Maternal immunisation against GBS during pregnancy might protect

40 ough scientific evidence to support maternal immunisation against pertussis and influenza is rapidly

41 2007 to form the Journalists Initiatives on Immunisation Against Polio (JAP), to develop communicati

42 e promising for the development of an active immunisation against tumours.

43 ary opportunities to expand the portfolio of immunisations against viral and bacterial diseases and t

44 ecuited infants due to receive their primary immunisations aged up to 13 weeks on first vaccinations

45 After boost immunisation, all vaccine regimens induced detectable an

46 We review the available evidence on maternal immunisation among women living with HIV (WLWH) for all

47 ent quantification of residual BCG from i.n. immunisation and allow accurate MTB quantification.

48 ons that can be routinely scheduled, such as immunisation and antenatal care, had much higher coverag

49 require improvements to presently inadequate immunisation and health-service infrastructures, and uni

50 , those examined in our study indicated that immunisation and immunotherapy with DFTD cells expressin

51 in coverage of interventions, especially of immunisation and insecticide-treated bednets.

52 e iNKT cell TCR repertoire changes following immunisation and is shaped by age and environmental chan

53 effective dose-sparing strategy for routine immunisation and outbreak responses.

54 8.5%) and has achieved universal coverage of immunisation and skilled birth attendance, with low ineq

55 iments that are done at long intervals after immunisation and that identify protection as the absence

56 The public needs to regain confidence in immunisation and trust the organisations responsible for

57 he remaining eight participants who received immunisation and who were examined neuropathologically,

58 evelopment of an infant's immune response to immunisations and unrelated infections.

59 s types 1, 2, and 3 at age 22 weeks (routine immunisation) and age 26 weeks (outbreak response).

60 o fIPV doses versus one IPV dose for routine immunisation, and also assessed the immunogenicity of an

61 We collected serum samples before and after immunisation, and cord blood from a subset of women and

62 21-51% in 2012 for routine and supplementary immunisation, and most caregivers cited ignorance of eit

63 lnutrition, indoor air pollution, incomplete immunisation, and paediatric HIV), with the exception of

64 ternative to conventional needle-and-syringe immunisation, and potentially offer improved immunogenic

65 prevention indicators (antenatal care, full immunisation, and screening for breast and cervical canc

66 idence for maternal and paediatric influenza immunisation, and should inform future immunisation poli

67 f oral polio vaccine (OPV) and other routine immunisations, and to enhance immunity through the intro

68 This immunisation approach should be considered for induction

69 m selected populations by means of universal immunisation as soon as suitable vaccines become license

70 roviding more immediate protection than does immunisation as well as providing additional protection

71 re significantly more likely to achieve full immunisation at 12 months of age (relative risk 1.09, 95

72 outine immunisation at 9 months, and routine immunisation at 9 months with catch-up campaigns to eith

73 red four strategies: no vaccination, routine immunisation at 9 months, and routine immunisation at 9

74 Universal hepatitis B immunisation at birth and in infancy is the key strategy

75 itamin A capsule receipt, complete childhood immunisations, better sanitation, and use of iodised sal

76 cosylation cleared red cells and prevented D-immunisation but less effectively than anti-D Ig.

77 s is almost completely preventable by active immunisation, but very rarely unexpected cases can occur

78 llowed up achieved the primary outcome, full immunisation by 12 months of age (296 [82%] of 360 contr

79 ity engagement and maternal and child health immunisation campaigns in insecure and conflict-affected

80 d health and immunisation camps during polio immunisation campaigns was successful in increasing vacc

81 tion and targeted community-based health and immunisation camps during polio immunisation campaigns w

82 realisation of the public health gains that immunisation can achieve in the next decade and beyond--

83 tion according to either caregiver report or immunisation card.

84 .1%, 95% CI 3.4-22.7), expanded programme on immunisation centres (3.3%, 95% CI 0-6.9), and paediatri

85 nutrition centres, and expanded programme on immunisation centres) in paediatric populations in low-i

86 recruited healthy infants aged 6 weeks at 42 immunisation clinics and randomly assigned them (with bl

87 group of consecutive babies who presented to immunisation clinics at the primary health-care centres,

88 fants younger than 9 months who presented to immunisation clinics at these five centres, using an ELI

89 ased condom use, more frequent screening and immunisation, concluding that the latter shows great pro

90 Maternal immunisation could be a promising strategy to reduce inf

91 improved routine or supplementary (campaign) immunisation coverage (multivariable odds ratio [OR] = 0

92 d health staff correlated significantly with immunisation coverage across many world regions.

93 In the 21st century, increases in immunisation coverage and decreases in under-5 mortality

94 upled with incentives significantly improved immunisation coverage and timeliness.

95 Incomplete immunisation coverage causes preventable illness and dea

96 Survey-based DTP3 immunisation coverage has improved more gradually and no

97 index: a summary measure of the strength of immunisation coverage in a country.

98 pending (0.66, p<0.0001) were informative of immunisation coverage in the Eastern Mediterranean betwe

99 Although immunisation coverage is reported administratively acros

100 Given that global immunisation coverage levels have stagnated around 85%,

101 ERPRETATION: In a setting with high baseline immunisation coverage levels, SMS reminders coupled with

102 to evaluate the acceptability and effect on immunisation coverage of an integrated strategy for comm

103 ll parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus tox

104 ate the child deaths that could be caused by immunisation coverage reductions during COVID-19 outbrea

105 s have been invested in increasing childhood immunisation coverage through global initiatives such as

106 Factors associated with DTP3 immunisation coverage varied by world region: personal i

107 dered a key solution to improving the global immunisation coverage.

108 f the immune responses following ID93/GLA-SE-immunisation demonstrated that ID93/GLA-SE was able to e

109 success of tetanus, influenza, and pertussis immunisation during pregnancy has led to consideration o

110 Immunisation during pregnancy is a relatively new strate

111 Influenza immunisation during pregnancy is recommended but not wid

112 imilarly, many countries recommend influenza immunisation during pregnancy to reduce the risk of dise

113 tetanus, diphtheria, and acellular pertussis immunisation during pregnancy.

114 asic vaccines from the Expanded Programme of Immunisation (eg, BCG, measles, diphtheria-tetanus-pertu

115 tio) to receive PCV10 in addition to routine immunisations either as a two-dose prime and boost (2+1)

116 ss of the recommended Expanded Programme for Immunisation (EPI) vaccines, this paper identifies predi

117 accine included in the Expanded Programme on Immunisation (EPI).

118 Immunisation experiments performed in rabbits demonstrat

119 scaled up selective primary health care (eg, immunisation, family planning), and 14 have progressed t

120 : maternal and newborn health, child health, immunisation, family planning, HIV/AIDS, and malaria.

121 hild mortality impact estimates of childhood immunisation for diphtheria, tetanus, pertussis, hepatit

122 Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, H

123 =320 and 284), given at the second and third immunisations for diphtheria, pertussis, and tetanus, an

124 outinely given vaccines require two or three immunisations for full protective efficacy.

125 tegy of the Global Alliance for Vaccines and Immunisation (GAVI) Alliance is helping to implement vac

126 es that the Global Alliance for Vaccines and Immunisation (GAVI) face now that these new vaccines are

127 (SIAs) and Global Alliance for Vaccines and Immunisation (GAVI) funding in replacing disposable and

128 aign and the Global Alliance on Vaccines and Immunisations (GAVI).

129 Following intramuscular immunisation, GBS67-CpGODN+L formed a vaccine depot at t

130 uenza infections in infants aged 0-6 months, immunisation had an overall efficacy for the combined co

131 For drug discovery, cow immunisations harness the immune system to generate knob

132 In African populations, infant immunisation has been fundamental to reducing incident i

133 Maternal immunisation has the potential to substantially reduce m

134 ternal and child health services and routine immunisation (health camps), including OPV (arm B), or a

135 hs prevented by sustaining routine childhood immunisation in Africa outweigh the excess risk of COVID

136 lth benefits of sustaining routine childhood immunisation in Africa with the risk of acquiring severe

137 be prevented by sustaining routine childhood immunisation in Africa.

138 and infants of year-round maternal influenza immunisation in Nepal, where influenza viruses circulate

139 y and memory are well understood to underpin immunisation in vertebrates, it has been somewhat surpri

140 e at age 1 year to BCG, tetanus, and measles immunisation; incidence of infectious diseases during in

141 al strategy was either no vaccination or TCV immunisation including a catch-up campaign.

142 Coverage of child immunisation increased the most (21% of children in 2000

143 hat gathered experts across several maternal immunisation initiatives-group B streptococcus, respirat

144 Mucosal immunisation is considered essential to initiate this re

145 Immunisation is possible with monovalent varicella vacci

146 d Kingdom Joint Committee on Vaccination and Immunisation (JCVI) recommended removal of one primary d

147 s are undergoing clinical trials, so passive immunisation might finally become an accessible, afforda

148 Finally, an in vivo immunisation model showed that BCG vaccination under PD-

149 To assess the suitability of a mouse immunisation model to study this phenomenon, we monitore

150 After booster immunisations, most of the immune responses showed the i

151 HPV immunisation of adolescent girls is expected to have a s

152 These data support the concept that immunisation of devils with DFTD cancer cells can succes

153 Immunisation of mice with different Opa variants elicite

154 pa bactericidal antibody responses following immunisation of mice with recombinant Opa were specific

155 onses in social ants that lead to the active immunisation of nestmates by infected individuals.

156 Immunisation of patients with Alzheimer's disease with f

157 The data support the use of QIV for immunisation of PLWH, reveal distinct circulating CD4(+)

158 lth benefits of sustaining routine childhood immunisation on only the child deaths averted from measl

159 ully active bNAbs for application in passive immunisation or as an alternative for current HIV/AIDS a

160 ocused health programmes in family planning, immunisation, oral rehydration therapy, maternal and chi

161 Viral vectors are a potent immunisation platform, benefiting from intrinsic immuno-

162 uenza immunisation, and should inform future immunisation policy particularly in low-income and middl

163 edge regarding the immunobiology of maternal immunisation prevent the optimal design and application

164 was introduced into the Australian National Immunisation Program in 2007.

165 role of school nurses in delivering the HPV immunisation programme and their impact on minimising he

166 Building on a routine immunisation programme and using existing facilities and

167 interviewed, primarily school nurses and HPV immunisation programme coordinators.

168 In the routine immunisation programme in Brazil, PCV10 prevents invasiv

169 ningococcal disease-into the national infant immunisation programme in September, 2015.

170 rain were selected and used for the national immunisation programme in the United Kingdom: an adjuvan

171 UK The HPV immunisation programme is primarily delivered by school

172 implemented 4CMenB into the national infant immunisation programme, alongside an emergency adolescen

173 A strategy modelled after China's immunisation programme, whereby care is provided close t

174 rotavirus vaccine into its routine national immunisation programme.

175 nB, Bexsero) into a publicly funded national immunisation programme.

176 6 and 14 weeks into South Africa's national immunisation programme.

177 le for one dose on the basis of the national immunisation programme.

178 ght modulate coverage could inform effective immunisation programmes and policies.

179 g understanding of the delivery processes of immunisation programmes and this impact on health inequa

180 troduced rotavirus vaccination into national immunisation programmes and, subsequently, the burden of

181 National immunisation programmes globally are at risk of suspensi

182 Rotavirus vaccine use in national immunisation programmes has led to declines in hospital

183 need to incorporate rotavirus vaccines into immunisation programmes in countries that have not yet i

184 red in the past decade as a direct result of immunisation programmes in Europe, Canada, and Australia

185 ive point-of-care test devices into existing immunisation programmes in primary health-care settings.

186 uccessful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high

187 screening into existing primary health-care immunisation programmes is feasible and can rapidly be i

188 nfluenza-associated disease burden, existing immunisation programmes might be less cost-effective.

189 whether measles cases are due to failure of immunisation programmes or vaccine policy failure, which

190 the need for improving the effectiveness of immunisation programmes that already exist.

191 pproximate measures of the susceptibility of immunisation programmes to coverage losses, with an aim

192 ctivated poliovirus vaccine (IPV) in routine immunisation programmes to eliminate vaccine-associated

193 cing OPV valence should be considered within immunisation programmes to reduce global enteric disease

194 e concerns over time and location could help immunisation programmes to tailor more effective and tim

195 the study suggests that routine infant PCV10 immunisation programmes will provide substantial direct

196 In combination with robust neonatal immunisation programmes, ongoing PMTCT efforts, and the

197 troduced rotavirus vaccine in their national immunisation programmes, rotavirus was detected in 38.0%

198 uced a rotavirus vaccine into their national immunisation programmes, we excluded data subsequent to

199 ssessments of the strength and resilience of immunisation programmes.

200 for the inclusion of Dengvaxia into existing immunisation programmes.

201 he UK following successful implementation of immunisation programmes.

202 ttractive target for preventive and reactive immunisation programmes.

203 ategies as crucial components in future mass immunisation programmes.

204 H1N1 strain, many countries have begun mass immunisation programmes.

205 ost or to discontinue PCV in their childhood immunisation programmes.

206 d funding to family planning, nutrition, and immunisation projects were noted in 2011 and 2012.

207 PCV13 immunisation provides a robust strategy for combating pn

208 igh number of doctors per head, high measles immunisation rates, few health-sector donors, and high d

209 inate in small, insular communities with low immunisation rates.

210 duled vaccinations according to the national immunisation recommendations and who lived in the county

211 Immunisation reduced maternal febrile influenza-like ill

212 Maternal immunisation reduced the rates of low birthweight by 15%

213 Whether maternal immunisation reduces the infectious morbidity and mortal

214 Up to now, immunisation regimens that have been assessed for develo

215 ata, sexual health clinic data, and National Immunisation Register data were linked via patients' uni

216 es were verified by the Australian Childhood Immunisation Register, which was also used to identify a

217 e was assessed from the Australian Childhood Immunisation Register.

218 were obtained from the Australian Childhood Immunisation Register.

219 biodistribution profile was reflected in the immunisation response, where lower levels of IgG2b antib

220 gate vaccine (PCV13) into the routine infant immunisation schedule in November 2011.

221 vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012.

222 he USA, IPV has been included in the routine immunisation schedule since 1997.

223 fter completion of the expanded programme of immunisation schedule): 1/3 IPV-Al 98.5% (n=202, type 1)

224 In 2010, PCV13 replaced PCV7 in the US immunisation schedule.

225 mococcal conjugate vaccine to the paediatric immunisation schedule.

226 nt protein subunit (CTH522) in a prime-boost immunisation schedule.

227 ction of vaccines might need modification of immunisation schedules and delivery procedures.

228 ntries opting for one dose of IPV in routine immunisation schedules during this transition because of

229 , 1980, to Nov 1, 2018, comparing poliovirus immunisation schedules in a primary series.

230 adication strategy to introduce IPV into the immunisation schedules of all countries.

231 tic test to determine serostatus, simplified immunisation schedules, and assessment of the need for b

232 assess the immunogenicity of bOPV in routine immunisation schedules.

233 44 phase 3 trial might benefit from extended immunisation schedules.

234 l immunity associated with different routine immunisation schedules.

235 age these technologies to support demand for immunisation services and improve vaccine coverage.

236 antenatal care, institutional delivery, and immunisation services in six of seven health districts i

237 -oriented initiatives such as UCI and GAVI's immunisation services support (ISS) might encourage over

238 op COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed.

239 Routine childhood immunisation should be sustained in Africa as much as po

240 NTERPRETATION: Year-round maternal influenza immunisation significantly reduced maternal influenza-li

241 for attachment informative behaviours in the immunisation situation should be developed and tested in

242 Following triple homologous immunisation, small unilamellar vesicles (SUVs) with no

243 of adverse events was similar regardless of immunisation status.

244 ild marriage, female genital mutilation, and immunisation), stigma and harm reduction, violence again

245 assess the potential effect of different RSV immunisation strategies (targeting vaccination for infan

246 Our results show that perinatal immunisation strategies for children aged younger than 6

247 led to consideration of additional maternal immunisation strategies to prevent group B streptococcus

248 al factors known to interfere with influenza immunisation, such as malaria, HIV, and malnutrition wer

249 education, and the strengthening of routine immunisation systems.

250 ventions against the two diseases to 80% and immunisation to 90% would eliminate more than two-thirds

251 ody gene delivery could be an alternative to immunisation to induce sustained expression of neutralis

252 requires two (IPV2) or three (IPV1 and IPV3) immunisations to induce similar responses.

253 als receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody ti

254 initiatives such as the Universal Childhood Immunisation (UCI) campaign and the Global Alliance on V

255 eminders and monetary incentives can improve immunisation uptake in Kenya.

256 OPV, IPV, and routine extended programme on immunisation vaccines and changes in the proportion of u

257 available for analysis 1 month after booster immunisation versus 86 in group 2.

258 are the relative immunogenicity of Nanopatch immunisation versus intramuscular injection in rats, usi

259 elivering both the component prime and boost immunisations via the airway is not well known.

260 Infant immunisation videos were observed and coded for parentin

261 ers before scheduled pentavalent and measles immunisation visits.

262 sis, aerosol delivery of MVA85A as a priming immunisation was well tolerated and highly immunogenic.

263 At 56 days post-immunisation, we found that rats with vasculitis had a s

264 Four primary immunisations, weekly for 4 weeks, containing Vacc-4x (o

265 Immune responses after subsequent immunisation were evaluated using haemagglutination-inhi

266 newborn babies and infants who presented for immunisation were screened for sickle cell disease at fi

267 Booster immunisations were given at weeks 16 and 18.

268 in antibody levels between baseline and post-immunisation, were assessed as secondary endpoints.

269 n in 15 (100%) of 15 participants after five immunisations, whereas no participants in the placebo gr

270 st rapid increases in coverage were seen for immunisation, which also received significant investment

271 after just one (IPV2) or two (IPV1 and IPV3) immunisations, while IM injection requires two (IPV2) or

272 ease antibody responses to gp140 after I.Vag immunisations, while in contrast PEI and Chitosan were a

273 Immunisation with 4CMenB or OMVs led to increased IL-6 i

274 e and non-human primates after intramuscular immunisation with a candidate recombinant measles vaccin

275 ndomisation system to receive transcutaneous immunisation with a patch containing 37.5 mug of ETEC LT

276 ctober, 2012, Fiji introduced routine infant immunisation with a ten-valent pneumococcal conjugate va

277 se I randomised, placebo-controlled trial of immunisation with Abeta(42) (AN1792, Elan Pharmaceutical

278 Although immunisation with Abeta(42) resulted in clearance of amy

279 ting tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of compet

280 ) to different single doses of intramuscular immunisation with ChAd3-EBO-Z: Malians received 1 x 10(1

281 Immunisation with either high-dose or low-dose DENVax fo

282 Immunisation with fully synthetic three-component vaccin

283 Immunisation with hepatitis B virus vaccine is the most

284 responses were attenuated in those reporting immunisation with influenza vaccine in the preceding thr

285 were reported in 14 (56%) of 25 after prime immunisation with intramuscular study product or placebo

286 ct or placebo, in 12 (33%) of 36 after prime immunisation with intranasal study product or placebo, a

287 product or placebo, in 22 (61%) of 36 after immunisation with intranasal study product or placebo, a

288 portionate reporting of adverse events after immunisation with IPV-containing vaccines compared with

289 e-poor countries has focused on early infant immunisation with little emphasis on protection in late

290 Although easily prevented by maternal immunisation with tetanus toxoid vaccine, and aseptic ob

291 Immunisation with the adjuvanted split vaccine induced s

292 t key serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), but i

293 enge was achieved after low dose (20PFU) pre-immunisation with this mutant.

294 ty, immunogenicity, and efficacy of maternal immunisation with trivalent inactivated influenza vaccin

295 rs from younger adults into aged mice and by immunisations with cholera toxin, without affecting germ

296 in vaginal secretions were achieved after IN immunisations with PEI and Chitosan.

297 nt benefit-risk ratios for routine childhood immunisation, with 95% uncertainty intervals (UIs) from

298 serum IgG antibody response after the prime immunisation, with a seven times increase in anti-H1 sta

299 ing antibodies in all dose cohorts after one immunisation, with seroconversion rates of 44% (n=4) in

300 d money if their child was timely immunised (immunisation within 2 weeks of the due date).